Compare CRC & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRC | IOVA |
|---|---|---|
| Founded | 2014 | 2007 |
| Country | United States | United States |
| Employees | 2500 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 1.7B |
| IPO Year | 2020 | 2008 |
| Metric | CRC | IOVA |
|---|---|---|
| Price | $54.42 | $10.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $72.57 | $9.00 |
| AVG Volume (30 Days) | 769.2K | ★ 13.1M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | N/A | ★ 14.84 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,669,000,000.00 | N/A |
| Revenue This Year | $12.37 | $47.74 |
| Revenue Next Year | N/A | $40.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 14.73 | N/A |
| 52 Week Low | $43.25 | $1.76 |
| 52 Week High | $71.98 | $10.98 |
| Indicator | CRC | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 51.07 | 72.59 |
| Support Level | $50.42 | $3.57 |
| Resistance Level | $55.01 | N/A |
| Average True Range (ATR) | 1.59 | 0.47 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 41.51 | 72.29 |
California Resources Corp is an independent oil and natural gas exploration and production company. The company has operations spread across different properties in several oil and gas exploration basins in California and Utah, such as the Midway-Sunset, South Belridge, and McKittrick fields, in the San Joaquin Basin, and other properties located in Los Angeles, Sacramento, Uinta, and the Ventura and Salinas basins. Additionally, the company is focused on maximizing the value of its land, mineral ownership, and energy expertise for decarbonization by developing carbon capture and storage (CCS) and other emissions-reducing projects. Its business is organized into two reporting segments: oil and natural gas, which generate maximum revenue, and carbon management.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.